Abbott India Limited (ABBOTINDIA.NS) fair value

ACCE thesis

Abbott India makes branded generic and specialty pharmaceuticals for the Indian market, sold under familiar names across gastroenterology, women's health, pediatrics and cardiology, with a large field sales force behind the brands. Its moat rests on brand trust with doctors and a distribution network that a new entrant would take years to replicate, which is visible in a 47.2% gross margin and a 27.7% operating margin. The near-term growth question is whether revenue, currently growing 4.3%, can re-accelerate as new launches and price increases feed through, since that is the difference between a stable compounder and a stock that is expensive for its current growth. At 33.4 times trailing earnings and 28.1 times forward, the market is already paying for steady execution, so the valuation leaves little room for a further slowdown in top-line growth. The thesis is worth a deeper look mainly to test the growth re-acceleration case against the price, not because the margins alone make the case.